Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA
Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA |
| [02-January-2025] |
LOS ANGELES, Jan. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the federal securities laws.
Shareholders who bought the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact DJS Law Group before January 17, 2025. CASE DETAILS: According to the Complaint, Humacyte allegedly made false statements regarding it failure to maintain good manufacturing practices including with its microbial testing at its Durham, North Carolina facility. The FDA's review of the Company's Biologic License Application (BLA) would be delayed while it fixed its manufacturing problems. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT:
SOURCE DJS Law Group LLP | ||
Company Codes: NASDAQ-NMS:HUMA |
View original content to download multimedia:
